Page 17 - Mylan EpiPen
P. 17
In all, the company's stock had gone from almost $58 a
share in January 2016 to $38, a 34 percent drop, in January
2017.
Mylan Share Price
In June, 2017 the Institutional Shareholder Services (Mylan
investment funds) criticized Mylan for the "outsized
compensation" of Mylan's directors. The report urged
Mylan's shareholders to vote against the re-election of the
company's directors after it paid Chairman Robert Coury
over $97 million in 2016 citing that the EpiPen price
increases and executive salaries caused “significant
destruction in shareholder value” and “long-term
reputational damage.” The directors were re-elected.
Source: Egan, Matt. "EpiPen maker faces revolt over exec's
$98 million pay package". CNN Money
